No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature businesses, turnarounds, and outright buyouts. The company primarily directs its capital towards businesses within the healthcare sector, focusing on medical equipment and services, biotechnology, life sciences, and pharmaceuticals. It actively seeks unlisted, small to mid-sized companies located predominantly across Northern Europe. Equity investments typically fall within the SEK 25 million to SEK 150 million range (approximately $2.75 million to $16.51 million). Target companies generally exhibit an enterprise value and annual sales revenue between SEK 50 million and SEK 200 million ($5.90 million to $23.06 million), alongside an EBITDA of SEK 1 million to SEK 50 million ($0.11 million to $5.50 million). MedCap aims to acquire ownership stakes of 20% to 50% in its portfolio entities, financing these through its own capital, loans, and direct balance sheet investments. Established in 2001, the firm maintains its headquarters in Stockholm, Sweden.
www.medcap.seNo one on the platform currently holds MCAP.ST.
No tracked institution reports a position in MCAP.ST as of their last filing.
No one on the platform has traded MCAP.ST yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.6% | 14.9% | — | — | — | |
| Rev. Growth % | 16.7% | 20.9% | ||||
| Profit Margin % | 10.4% | 10.8% | 6.9% | |||
| Free Cash Flow Margin % | 13.3% | 10.2% | 8.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.4B | +15.6% | $23.07 | $20.13–$26.01 | — | 1 |
| 2027 | $2.6B | +10.0% | $26.47 | $24.75–$28.19 | — | 1 |
| 2028 | $2.9B | +8.4% | $29.22 | $28.04–$30.41 | — | 1 |
| 2029 | $3.2B | +11.5% | $31.54 | $30.26–$32.82 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-21 | $4.71 | $5.25 | +11.5% |
| 2026-04-29 | $4.67 | $4.43 | -5.1% |
| 2026-02-06 | $4.76 | $4.90 | +2.9% |
| 2025-10-24 | $3.20 | $3.41 | +6.6% |
| 2025-07-23 | $3.60 | $3.57 | -0.8% |
| 2025-04-29 | $3.40 | $3.40 | +0.0% |
| 2025-01-31 | $2.80 | $2.79 | -0.4% |
| 2024-10-25 | $3.20 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| MCAP.STMedCap AB (publ) | $527.00 | +0.96% | $7.9B | — |
| CRED-A.STCreades AB | $90.85 | +1.06% | $12.3B | — |
| CS.STCoinShares International Limited | $72.30 | +0.00% | $4.7B | — |
| HOFI.STHoist Finance AB (publ) | $203.60 | +0.79% | $17.8B | — |
| KARNEL-B.STKarnell Group AB ser. B | $94.90 |
| $3.54 |
| +10.6% |
| -2.77% |
| $5.1B |
| — |
| ORES.STInvestment AB Öresund (publ) | $144.40 | -0.41% | $6.4B | — |
| RATO-B.STRatos AB (publ) | $37.16 | -0.69% | $12.2B | — |
Source: Financial Modeling Prep · peers by sector/industry